Science Immunology

The PDF file includes:

  • Fig. S1. Study design and participant overview.
  • Fig. S2. SARS-CoV-2 rRT-PCR cycle threshold (Ct) values for diagnostic nasopharyngeal (NP) swabs.
  • Fig. S3. Distribution and trajectories of antibody responses to SARS-CoV-2 in inpatients over time.
  • Fig. S4. Distribution and trajectories of antibody responses to SARS-CoV-2 in outpatients over time.
  • Fig. S5. Development of anti-SARS-CoV-2 spike S1 antibody responses in COVID-19 patients.
  • Fig. S6. Development of anti-SARS-CoV-2 N antibody responses in COVID-19 patients.
  • Fig. S7. Comparison of antibody responses against SARS-CoV-2 antigens among ICU patients who survived or died.
  • Fig. S8. COVID-19 inpatients develop anti-SARS-CoV/SARS-CoV-2 spike RBD cross-reactive IgG responses.
  • Fig. S9. Pseudoviral neutralization activity in longitudinal samples from the validation cohort.
  • Fig. S10. Correlations between anti-SARS-CoV-2 spike RBD antibody responses, pseudoviral neutralization activity, and viral RNA in individual hospitalized patients.
  • Fig. S11. Correlations between anti-SARS-CoV-2 spike RBD antibody responses, pseudoviral neutralization activity, and viral RNA in individual ICU and deceased patients.
  • Fig. S12. Checkerboard titration for serological RBD ELISA.
  • Fig. S13. Validation of the Stanford Health Care Clinical Laboratory anti-RBD IgM/G ELISA.
  • Fig. S14. Checkerboard titration for receptor blocking ELISA.
  • Fig. S15. RBD-ACE2 blocking ELISA optimization.
  • Table S1. Demographic and clinical characteristics of outpatients and asymptomatic individuals with and without plasma availability.
  • Table S2. Inpatient seropositivity.
  • Table S3. Outpatient and asymptomatic individuals’ seropositivity.
  • Table S4. Determination of SARS-CoV-2 assay cutoff values and specificity.

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S5. Raw data file (Excel spreadsheet).